C-RBEERubedo Life Sciences
senescent cells, GPX4 modulation, drug discovery platform
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-RBEE
C-RBEEC-RBEEsenescent cells, GPX4 modulation, drug discovery platform
0-100 chain-logic scale · 15 dimensions · scored on public evidence
In this episode of The Pauling Principle I sit with Marco Quarta, Founder and current CSO of Rubedo and we discuss cellular senescence, one of the most prominent causes of aging, and a variety of potential therapies. As well as Rubedo recent positive phase I clinical trial. https://www.rubedolife.com/about/
This clinical trial will assess the safety and tolerability of topical application of RLS-1496 cream to lesions and adjacent skin on the left forearm of adults with actinic keratoses (AK) on the arms. The right forearm will remain untreated as a control. The therapeutic objective of topical treatment with RLS-1496 cream is to clear or decrease the number of AK in the treated area, per lesion counts performed by the Investigator. The main questions it aims to answer are: * Is it safe to apply topical RLS-1496 cream to treat AK once daily for 28 days? * Does topical RLS-1496 lower the number of AKs or eliminate AKs in a treated area when applied once daily for 28 days? Researchers will compare results on the left (treated with RLS-1496) and right (no treatment) forearm. Participants will apply RLS-1496 to an identified area on the left forearm once each day for 28 days and have intermittent clinic visits to examine the arms and have the AK lesions counted until 28 days after the last application of RLS-1496. Participants will also have small skin biopsies on the arms.
In this episode, Patrick is joined by Marco Quarta, Co-founder and CEO of Rubedo Life Sciences, and previously Director of Bioengineering in Stem Cells and Regenerative Medicine at Stanford University. Since childhood, Marco had the dream of “curing” aging and his work at Rubedo focuses on understanding cell senescence, with the goal of developing novel therapies for age-linked diseases. Join Marco and Patrick as they discuss his transition from academia to founding multiple companies, why not all senescent cells are equal, and how understanding the processes behind cell aging could help extend human healthspan. 0:00 Intro to The Genetics Podcast 01:00 Welcome to Marco 02:00 The areas Marco focused on during his academic career and what motivated him to found his first company 03:18 How our understanding of aging has changed over the past two decades and some of the current big questions in aging biology 06:01 How to get a clearer picture of the aging process within a tissue or c
Another exciting interview from Forever Healthy's Rejuvenation Startup Summit. This time I was lucky enough to talk to Dr. Marco Quarta, CEO of Rubedo Life Sciences, who have another interesting approach in fighting senescent cells. 🔬 Highlights: - Rubedo uses a platform called Alembic, leveraging AI and genomics to identify and target specific senescent cells responsible for various diseases, allowing for the development of highly selective treatments. - The company's first drug, RLS-1496, is entering clinical trials this year to treat chronic inflammatory skin conditions. This drug is part of a broader effort to create therapies for different tissues, such as the lung and liver. - Rubedo has partnered with Beiersdorf to develop a cosmetic cream that uses their technology to rejuvenate aging skin, potentially providing a practical, non-medical anti-aging solution. 👀 Watch the interview and join the discussion. Let’s pursue the future of longevity together. 💬 What do you thi
https://www.raiplay.it/programmi/codicelavitaedigitale - Marco Quarta, è il founder di due startup – Rubedo Life Sciences e Turn Bio – che in Silicon Valley stanno lavorando sulla cosiddetta medicina della longevità.
#youtubeshorts from @ProgressPotentialPossibilities Dr. Marco Quarta, Ph.D. - Co-Founder and CEO, Rubedo Life Sciences; CEO, Phaedon Institute - Discovering And Developing Medicines To Keep You Biologically Young https://www.youtube.com/watch?v=yGS7yJ3YcJg #ProgressPotentialAndPossibilities #EricVerdin #VittorioSebastiano #CaliforniaInstituteForRegenerativeMedicine #Aging #Therapeutics #Longevity #Rejuvenation #StemCells #Senescence #CellularReprogramming
Marco Quarta, Co-founder and CEO of Rubedo Life Sciences presenting at the Rejuvenation Startup Summit 2024 Connect to Forever Healthy: * Videos: https://forever-healthy.org/videos/ * News: https://forever-healthy.org/news/ * LinkedIn: https://www.linkedin.com/company/forever-healthy-foundation
Age Reversal through new generation of Senolytics/ Dr Marco Quarta Dr. Marco Quarta, Ph.D. is Co-Founder and CEO of Rubedo Life Sciences ( https://www.rubedolife.com/), a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. The company's proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. ………………………………………………………………………………………… Please note that the following links are affiliate links, so we receive a small commission when you purchase a product through the links. Thank you for your support!!! The following products, I have personally tried and feel comfortable and confident recommending to you: 1. Nuchido Time+ Supplements FIRST ORDER 20% OFF Discount Code when chec
NOTE FROM TED: Research around aging discussed in this talk remains an ongoing field of study. TEDx events are independently organized by volunteers. The guidelines we give TEDx organizers are described in more detail here: http://storage.ted.com/tedx/manuals/tedx_content_guidelines.pdf What if I told you a secret: when you were born someone messed up with your birth certificate and your real age is actually 30 years older than what you actually think. And yet, you still feel much younger, don’t you?! Imagine for example that instead of being 50 years old you real age is actually 80! What would change for you? Nothing, really. And that is the most important point. You would continue to enjoy your life as is. This is exactly the point! Scienziato che, dal cuore della Silicon Valley, studia come invertire l'orologio biologico delle nostre cellule. Dopo aver conseguito un post-doc presso l’Università di Stanford, fonda due aziende biotech, Rubedo Life Sciences e Turn Bio, votate a tras
Dr. Marco Quarta, Ph.D. is Co-Founder and CEO of Rubedo Life Sciences ( https://www.rubedolife.com/ ), a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. The company's proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. Dr. Quarta received his doctorate degree in Biotechnology from the University of Bologna and a Ph.D. in Neuroscience from the University of Padua. He completed a post-doc in Aging and Stem cell Biology in the lab of Prof. Thomas Rando at Stanford University and continued his work at Stanford directing a research team at the Center for Tissue Regeneration, Repair, and Restoration at the VA Hospital in Palo Alto, CA. While there, he established
Dr. Marco Quarta, founder of Rubedo Life Sciences and Turn bio, has given a fabulous lecture on the 10th ARDD on topic of "Therapeutic targeting of cellular senescence heterogeneity across age-related diseases". Rubedo Life Sciences is aiming at developing treatments for chronic age-related diseases and extend healthy life by selectively targeting pathological cells involved in the biological aging process On the sidelines of the conference, he was interviewed by TimePie on the following questions: 1.We know that cellular senescence is one of the hallmarks of aging, so generally, people regard it as a totally bad thing, but is it really the case? 2.How many ways do we have or under-research that could reduce senescent cells? 3.Rubedo has a drug discovery platform that identifies specific targets and then develops therapies that selectively target senescent cells. Can you give more details about that?
The Aging and Drug Discovery Conference (ARDD) 2022 is pleased to present Marco Quarta from Rubedo Life Sciences, with the talk From single cell AI enabled discovery of cell senescense to target senolytic drug development. Held in Copenhagen at the glorious Ceremonial Hall, this meeting gathers the most prominent figures of the aging and longevity research field, from scientists to clinicians, investors, developers and everything in between. The fast growth of the conference is evidence its the great quality. In 2022 we had around 400 people on-site, and many others joined through the web. To find out more check www.agingpharma.org #ARDD #ARDD2022 #Longevity
Rejuvenative Medicine and Treating Ageing: Interview with Dr. Marco Quarta (Last part) Rejuvenative Medicine has different fields such as tissue-engineered products (inducing bone and tissue growth), and stem cells for treating many intractable diseases. The new fields include treating aging as a disease and trying to cure it so we can lead a longer healthy life by using novel techniques like removing organ cells and infusing new matter to the existing matrix to restore full functioning. Dr. Marco Quarta is a biomedical scientist at the School of Medicine of Stanford University, CA, USA. His research is focused on physiology, biomechanics and on bioengineering in regenerative medicine and aging biology. He is also serial entrepreneur, co-founder of longevity biotech companies in Europe and in the Silicon Valley in California, such as Rubedo Life Sciences (where he serves as CEO) and Turn Biotechnologies (where he served as CSO and serves as chief scientific advisor and director). He a
Rejuvenative Medicine and Treating Ageing: Interview with Dr. Marco Quarta (Part 2) Rejuvenative Medicine has different fields such as tissue-engineered products (inducing bone and tissue growth), and stem cells for treating many intractable diseases. The new fields include treating aging as a disease and trying to cure it so we can lead a longer healthy life by using novel techniques like removing organ cells and infusing new matter to the existing matrix to restore full functioning. Dr. Marco Quarta is a biomedical scientist at the School of Medicine of Stanford University, CA, USA. His research is focused on physiology, biomechanics and on bioengineering in regenerative medicine and aging biology. He is also serial entrepreneur, co-founder of longevity biotech companies in Europe and in the Silicon Valley in California, such as Rubedo Life Sciences (where he serves as CEO) and Turn Biotechnologies (where he served as CSO and serves as chief scientific advisor and director). He also
Rejuvenative Medicine and Treating Ageing: Interview with Dr. Marco Quarta (Part 1) Rejuvenative Medicine has different fields such as tissue-engineered products (inducing bone and tissue growth), and stem cells for treating many intractable diseases. The new fields include treating aging as a disease and trying to cure it so we can lead a longer healthy life by using novel techniques like removing organ cells and infusing new matter to the existing matrix to restore full functioning. Dr. Marco Quarta is a biomedical scientist at the School of Medicine of Stanford University, CA, USA. His research is focused on physiology, biomechanics and on bioengineering in regenerative medicine and aging biology. He is also serial entrepreneur, co-founder of longevity biotech companies in Europe and in the Silicon Valley in California, such as Rubedo Life Sciences (where he serves as CEO) and Turn Biotechnologies (where he served as CSO and serves as chief scientific advisor and director). He also
Learn about the top trends and technologies in Longevity and how industry is targeting senescence. Hosted by Prime Movers Lab Partner Jyothi Devakumar and General Partner Brandon Simmons Panelists include: Angele Maki, Vice President, Venture Science, Corporate Business Development at Eli Lilly Marco Quarta, Co-Founder & CEO at Rubedo Life Sciences Paul D. Robbins, Professor of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota
Anti-aging drugs targeting senescent cells: Marco Quarta Thu May 20, 2021 Q&A with Marco Quarta, co-founder of Rubedo Life Sciences, a longevity biotech company developing therapies that remove senescent cells with targeted approaches.
Italian Martial Arts: Interview with Dr. Marco Quarta (Part 3: Final Part) Dr. Marco Quarta is a biomedical scientist at the School of Medicine of Stanford University, CA, USA. His research is focused on physiology, biomechanics and on bioengineering in regenerative medicine and aging biology. He is also serial entrepreneur, co-founder of longevity biotech companies in Europe and in the Silicon Valley in California, such as Rubedo Life Sciences (where he serves as CEO) and Turn Biotechnologies (where he served as CSO and serves as chief scientific advisor and director). He also researches, teaches and promotes Italian Martial Arts (IMAs) at Stanford and in the San Francisco Bay Area. Overall, his work, as for Nova Scrimia philosophy, is dedicated to proposing original IMA traditions actualized in modern combat and self defense methods. You can check his websites here: https://www.italianmartialarts.org/?fbclid=IwAR1fEeCP2UrEynAwLsHJJLTnybgcUpXKhEKdBrWyfvzZ2krXD244KBnVPjA and https://w
Italian Martial Arts: Interview with Dr. Marco Quarta (Part 2) Dr. Marco Quarta is a biomedical scientist at the School of Medicine of Stanford University, CA, USA. His research is focused on physiology, biomechanics and on bioengineering in regenerative medicine and aging biology. He is also serial entrepreneur, co-founder of longevity biotech companies in Europe and in the Silicon Valley in California, such as Rubedo Life Sciences (where he serves as CEO) and Turn Biotechnologies (where he served as CSO and serves as chief scientific advisor and director). He also researches, teaches and promotes Italian Martial Arts (IMAs) at Stanford and in the San Francisco Bay Area. Overall, his work, as for Nova Scrimia philosophy, is dedicated to proposing original IMA traditions actualized in modern combat and self defense methods. You can check his websites here: https://www.italianmartialarts.org/?fbclid=IwAR1fEeCP2UrEynAwLsHJJLTnybgcUpXKhEKdBrWyfvzZ2krXD244KBnVPjA and https://www.novascrim
Italian Martial Arts: Interview with Dr. Marco Quarta (Part 1) Dr. Marco Quarta is a biomedical scientist at the School of Medicine of Stanford University, CA, USA. His research is focused on physiology, biomechanics and on bioengineering in regenerative medicine and aging biology. He is also serial entrepreneur, co-founder of longevity biotech companies in Europe and in the Silicon Valley in California, such as Rubedo Life Sciences (where he serves as CEO) and Turn Biotechnologies (where he served as CSO and serves as chief scientific advisor and director). He also researches, teaches and promotes Italian Martial Arts (IMAs) at Stanford and in the San Francisco Bay Area. Overall, his work, as for Nova Scrimia philosophy, is dedicated to proposing original IMA traditions actualized in modern combat and self defense methods. You can check his websites here: https://www.italianmartialarts.org/?fbclid=IwAR1fEeCP2UrEynAwLsHJJLTnybgcUpXKhEKdBrWyfvzZ2krXD244KBnVPjA and https://www.novascrim
Marco is the CEO and co-founder of Rubedo Life Sciences, a drug discovery company with the mission to develop treatments for age-related diseases and extend health span using targeted small molecule therapies. As a scientist, he earned a Master’s degree in Biotechnology at University of Bologna (Italy), a PhD in Neuroscience at University of Padua (Italy), and post-doctoral training in Aging, Stem Cells Biology, and Regenerative Medicine at Stanford University School of Medicine (California). He then directed at Stanford/VA Hospital Palo Alto a research team focused on translational medical research in the fields of aging and regenerative medicine. He is backed by over 15 years of research with an extensive track record of scientific publications in top tier journals (such as Nature, Science, Nature Biotechnology, Cell Stem Cell). Furthermore, he is an inventor on U.S. patents. As an entrepreneur and biotech-manager, Marco first started as an undergrad student when he co-founded Young
https://Twitter.com/BrentNally https://Patreon.com/BrentNally https://Linkedin.com/in/BrentNally https://Instagram.com/Brent.Nally https://Facebook.com/Brent.Nally https://Reddit.com/user/BrentNally Clubhouse @BrentNally Discord Brent Nally TikTok @brentnally Telegram https://t.me/brentnally https://medium.com/@BrentNally https://BrentNally.tumblr.com Snapchat BrentNally - My mission is to solve the human aging problem ASAP. - Please consider donating: https://paypal.me/BrentNally or my Bitcoin Cash (BCH) address: qr9gcfv92pzwfwa5hj9sqk3ptcnr5jss2g78n7w6f2 or Patreon - Please also subscribe, click the bell & click "all notifications" on these YouTube channels: https://youtube.com/LifespanNews https://youtube.com/LifespanIO https://youtube.com/Longevityy https://youtube.com/DrBradStanfield https://youtube.com/TheSheekeyScienceShow https://youtube.com/VitaDAO https://youtube.com/SiimLand https://youtube.com/Transhumania https://youtube.com/EternalLifeFan https://youtube.com/c/For